44TiP ENGOT-ov65/KEYNOTE-B96: Phase III, randomized, double-blind study of pembrolizumab vs placebo + paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer
作者
N. Colombo,Robert Louis Coleman,Xiaohua Wu,Fatih Kose,Robert M. Wenham,Alexandra Sebastianelli,K. Hasegawa,E. Zsiros,Thibault De La Motte Rouge,Mariusz Bidziński,Iain A. McNeish,Jalid Sehouli,J. Korach,Philip R. Debruyne,JW Kim,Andréia Cristina de Melo,X. Peng,Agata M. Bogusz,K.U. Yamada,Bradley J. Monk